CAMS & PUMC Held International Symposium on Drug-resistant Tuberculosis Diagnosis and Treatment

2016-09-15

International Symposium on Drug-resistant Tuberculosis Diagnosis and Treatment organized by the joint effort of the Chinese Academy of Medical Sciences (CAMS), Chinese Center for Disease Control and Prevention and the French Mérieux Institute, was held on September 13-14 at CAMS & PUMC Auditorium, an elegant venue with rich cultural heritage. The Symposium invited nearly 100 domestic and international experts and scholars in the field of TB diagnosis and treatment. Following the format of special reports and expert-led in-depth discussions, these scientists exchanged ideas and discussed common issues in clinical diagnosis and treatment of tuberculosis; they also shared the latest research development and results. Mr. Benoit Sevcik, Public Affairs Counsellor of Embassy of France in China, and Ms. Qizhi Liao, Chief Representative of Mérieux Institute and Foundation in China, attended the opening ceremony.



Mr. Xuetao Cao, President of the Symposium and President of CAMS & PUMC, and Professor Marc Bonneville, Vice President of Mérieux Institute, delivered speeches at the opening ceremony. President Cao extended his warm welcome and sincere gratitude to all the participating guests; he remarked that CAMS & PUMC valued and supported the basic and clinical research on tuberculosis, to which the treatment and prevention, especially to drug-resistant TB, is a national demand; he also conveyed his expectation on and offered suggestions to the globalization of TB and drug-resistant TB research. Professor Marc Bonneville, Vice President of Mérieux Institute, gave a detailed introduction to the Institute’s work on infectious diseases, the effort of Mérieux Foundation in supporting TB diagnosis and the latest developments of TB research, among others. Both chairmen of the Symposium stated that innovation was the key to the development of medical sciences and the solution to public health problems.


 


The two-day symposium was aimed to introduce the latest development, challenges and opportunities of in vitro diagnostic methods for multidrug-resistant tuberculosis, to explore clinical needs and cost-effectiveness of drug-resistant TB diagnostic methods, and to share the experience from different hospitals in drug-resistant TB diagnosis and treatment and in their operational management. Dr. Christopher Gilpin from the World Health Organization (WHO) first introduced WHO’s mid- and long-term goals to eliminate TB, recommended TB diagnosis policies to the global community and then discussed the progress, prospect, and existing limitations in detecting drug-resistant tuberculosis. His talk followed by the invited speakers’ presentations on such topics as new drug-resistant TB diagnostic methods and cost-effectiveness calculation, the actual impact of existing diagnostic methods on the clinical diagnosis and treatment of multidrug-resistant tuberculosis, and drug-resistant TB treatment and hospital management. At the same time, experts from home and abroad were engaged in a lively discussion on related issued from five perspectives, drawing experience from one another and offering unique insights. They also had in-depth discussions on China’s opportunity, strength and limitation in modifying and implementing researches on drug-resistant TB diagnostic methods.



The participating guests took full advantage of this symposium as an exchange platform to share experiences and learn from one another in clinical diagnosis and treatment of drug-resistant tuberculosis, hoping to integrate the world’s advanced technology into the clinical diagnosis and treatment, to better connect the actual needs of clinical diagnosis with the laboratory studies, to effectively solve practical problems in the TB diagnosis and treatment, and to advance the clinical TB diagnosis and treatment in China even globally. CAMS representatives and their foreign counterparts held discussions on the content and form of in-depth cooperation and exchanges, laying the foundation to extend the cooperation into relevant areas. This symposium was significant in terms of increasing and deepening exchanges between China and the global community in medical research and health sciences, as well as fostering and facilitating cooperation among medical research institutions in different countries and clinical organizations in TB and related studies.

 

(Institute of Pathogen Biology)